NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Stifel Nicolaus
Stock analysts at Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $44.00 price target on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 114.63% from the […]
Stock analysts at Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $44.00 price target on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 114.63% from the […]
